OBJECTIVE: To investigate the effects of the selective Rho-associated protein kinase (ROCK) inhibitor azaindole-1 on erectile function under physiologic and pathophysiologic conditions in the rat. METHODS: The effect of intracavernosal (i.c.) injections of azaindole-1 on change in intracavernous pressure (ICP), ICP/mean arterial pressure (MAP), area under the curve (AUC), and response duration were investigated in the anesthetized rat under control conditions and when nonadrenergic noncholinergic neurotransmission and cholinergic function or soluble guanylyl cyclase (sGC) were inhibited or after cavernosal nerve crush injury. RESULTS: The i.c. injections of azaindole-1 produced dose-related increases in ICP/MAP and AUC that were long-lasting at the highest doses studied compared with the prototypical ROCK inhibitor fasudil. Erectile responses were not altered by 7-nitroindazole and atropine in doses that reduced the response to cavernosal nerve stimulation by 86%, indicating that they were independent of NO release by cavernosal nerves or activation of muscarinic receptors in the corpora cavernosa. Erectile responses to azaindole-1 were not altered by the sGC inhibitor ODQ in a dose that attenuated responses to the NO donor sodium nitroprusside, indicating that they were independent of an action on sGC. The erectile response to i.c. injections of azaindole-1 or Y-27632, which was reported to be NO/cyclic guanosine monophosphate-dependent, was not attenuated after cavernosal nerve crush injury. CONCLUSION: The present studies indicate that azaindole-1 has long-lasting erectile activity that is independent of NO release, muscarinic receptor, or sGC activation or the integrity of the cavernosal nerves.
OBJECTIVE: To investigate the effects of the selective Rho-associated protein kinase (ROCK) inhibitor azaindole-1 on erectile function under physiologic and pathophysiologic conditions in the rat. METHODS: The effect of intracavernosal (i.c.) injections of azaindole-1 on change in intracavernous pressure (ICP), ICP/mean arterial pressure (MAP), area under the curve (AUC), and response duration were investigated in the anesthetized rat under control conditions and when nonadrenergic noncholinergic neurotransmission and cholinergic function or soluble guanylyl cyclase (sGC) were inhibited or after cavernosal nerve crush injury. RESULTS: The i.c. injections of azaindole-1 produced dose-related increases in ICP/MAP and AUC that were long-lasting at the highest doses studied compared with the prototypical ROCK inhibitor fasudil. Erectile responses were not altered by 7-nitroindazole and atropine in doses that reduced the response to cavernosal nerve stimulation by 86%, indicating that they were independent of NO release by cavernosal nerves or activation of muscarinic receptors in the corpora cavernosa. Erectile responses to azaindole-1 were not altered by the sGC inhibitor ODQ in a dose that attenuated responses to the NO donorsodium nitroprusside, indicating that they were independent of an action on sGC. The erectile response to i.c. injections of azaindole-1 or Y-27632, which was reported to be NO/cyclic guanosine monophosphate-dependent, was not attenuated after cavernosal nerve crush injury. CONCLUSION: The present studies indicate that azaindole-1 has long-lasting erectile activity that is independent of NO release, muscarinic receptor, or sGC activation or the integrity of the cavernosal nerves.
Authors: M E Sullivan; C S Thompson; M R Dashwood; M A Khan; J Y Jeremy; R J Morgan; D P Mikhailidis Journal: Cardiovasc Res Date: 1999-08-15 Impact factor: 10.787
Authors: B K Dahal; D Kosanovic; P K Pamarthi; A Sydykov; Y-J Lai; R Kast; H Schirok; J-P Stasch; H A Ghofrani; N Weissmann; F Grimminger; W Seeger; R T Schermuly Journal: Eur Respir J Date: 2010-06-07 Impact factor: 16.671
Authors: Edward A Pankey; Ryuk J Byun; William B Smith; Manish Bhartiya; Franklin R Bueno; Adeleke M Badejo; Johannes-Peter Stasch; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz Journal: Can J Physiol Pharmacol Date: 2012-05-16 Impact factor: 2.273
Authors: V Sauzeau; H Le Jeune; C Cario-Toumaniantz; A Smolenski; S M Lohmann; J Bertoglio; P Chardin; P Pacaud; G Loirand Journal: J Biol Chem Date: 2000-07-14 Impact factor: 5.157
Authors: Edward A Pankey; Manish Bhartiya; Adeleke M Badejo; Umair Haider; Johannes-Peter Stasch; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz Journal: Am J Physiol Heart Circ Physiol Date: 2011-01-07 Impact factor: 4.733
Authors: Christian Gratzke; Travis D Strong; Milena A Gebska; Hunter C Champion; Christian G Stief; Arthur L Burnett; Trinity J Bivalacqua Journal: J Urol Date: 2010-09-18 Impact factor: 7.450
Authors: R Kast; H Schirok; S Figueroa-Pérez; J Mittendorf; M J Gnoth; H Apeler; J Lenz; J K Franz; A Knorr; J Hütter; M Lobell; K Zimmermann; K Münter; K H Augstein; H Ehmke; J P Stasch Journal: Br J Pharmacol Date: 2007-10-15 Impact factor: 8.739
Authors: George F Lasker; Edward A Pankey; Terrence J Frink; Jonathan R Zeitzer; Korey A Walter; Philip J Kadowitz Journal: Am J Physiol Heart Circ Physiol Date: 2013-04-12 Impact factor: 4.733
Authors: Vincent de Kemp; Petra de Graaf; Joost O Fledderus; J L H Ruud Bosch; Laetitia M O de Kort Journal: PLoS One Date: 2015-02-17 Impact factor: 3.240